The global discourse surrounding the management of Attention-Deficit Hyperactivity Disorder (ADHD) frequently centers on methylphenidate, the active pharmacological agent in medications like Ritalin. As awareness of neurological health grows, patients and researchers alike are seeking to understand how this stimulant is classified, regulated, and integrated into treatment programs across diverse jurisdictions, including the UK, Germany, […]